Delivery Order SPE2DB22D1202-SPE2DB25FVLH5
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,124.16 to AmerisourceBergen Drug Corp for Naloxone HCL 4 mg nasal spray (2-count units) on August 22, 2025, with completion scheduled for August 25, 2025. This firm fixed price contract was awarded competitively with no set-aside designation and is being performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,928.40 to AmerisourceBergen Drug Corp for Naloxone HCl 4 mg nasal spray (2-count units) on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed-price, non-set-aside contract is classified as a child award, indicating it derives from a larger contract vehicle. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $1,519.77 to AmerisourceBergen Drug Corp for Naloxone HCl 4 mg nasal spray (2-count units) on August 18, 2025, with completion targeted for August 19, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply framework. Performance will be executed from the company's Conshohocken, Pennsylvania location,...
- The Defense Logistics Agency awarded a delivery order valued at $10,266.71 to AmerisourceBergen Drug Corp for the supply of Naloxone HCl 4 mg nasal spray. This contract, which was competitively awarded with no set-aside designation, has a firm fixed price structure and an ultimate completion date of August 18, 2025. The product will be delivered to a location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under...
- The Defense Logistics Agency awarded a $1,653.49 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Naloxone HCL 4 mg nasal spray (2-count units). The contract, which was competitively awarded with no set-aside designation, is scheduled for completion by August 5, 2025, and will be performed at the awardee's Conshohocken, Pennsylvania location. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Naloxone HCL 4 mg nasal spray with a ceiling value of $1,100.49. This firm fixed-price delivery order, with an ultimate completion date of June 2, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award was made on...
- The Defense Logistics Agency awarded a delivery order valued at $1,572.48 to AmerisourceBergen Drug Corp for Naloxone HCL 4 mg nasal spray (2-count units) on September 3, 2025, with an ultimate completion date of September 4, 2025. This firm fixed-price delivery order, issued without set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract SPE2DX), valued at...
- The Defense Logistics Agency awarded a delivery order valued at $1,799.28 to AmerisourceBergen Drug Corp for the supply of Naloxone HCl 4 mg nasal spray (2-pack units). This contract was competitively awarded with no set-aside designation and operates under a firm fixed price structure. The work is scheduled for completion by August 15, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order valued at $1,301.63 to AmerisourceBergen Drug Corp for the supply of Naloxone HCL 4 mg nasal spray (2-pack units) on July 23, 2025, with completion required by July 24, 2025. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion comprehensive pharmaceutical supply vehicle running through December 2026. The...
- The Defense Logistics Agency awarded a $4,498.38 delivery order to AmerisourceBergen Drug Corp for Naloxone HCl 4 mg nasal spray (2-dose units) on July 14, 2025, with a completion date of July 15, 2025. This competitively awarded, firm fixed-price contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The order will be fulfilled from the contractor's...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVLH5Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,686.24 to AmerisourceBergen Drug Corp for the supply of Naloxone HCl 4 mg nasal spray (2-count units) on September 15, 2025, with completion scheduled for September 16, 2025. This firm fixed-price delivery order was competitively awarded without a set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The prime IDC vehicle enables AmerisourceBergen to supply a comprehensive range of pharmaceutical products and medical supplies globally, including specialty medications, vaccines, and medical devices across multiple therapeutic domains. This delivery order for naloxone, a life-saving opioid antagonist, aligns with the company's extensive portfolio of federal medical supply contracts and demonstrates its role in supporting Department of Defense healthcare operations and readiness requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 9/15/25 |